← Oncology Approval Tracker

FDA DECISION ·

Opdivo Qvantig

nivolumab + hyaluronidase-nvhy · Bristol Myers Squibb

Traditional approvalTraditional conversionHepatocellular carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

As subcutaneous monotherapy for adults with unresectable or metastatic hepatocellular carcinoma after prior sorafenib and IV nivolumab plus ipilimumab combination therapy.

LAMPGEN ANALYSIS

Why it matters

FDA converted the post-sorafenib use of the subcutaneous formulation from accelerated to traditional approval.

What research teams should watch

Verify the sorafenib and IV immunotherapy history before applying the converted label.

PRIMARY RECORDS

Sources